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Cardiac myosin is the molecular motor that powers heart
contraction by converting chemical energy from ATP hydro-
lysis into mechanical force. The power output of the heart is
tightly regulated to meet the physiological needs of the body.
Recent multiscale studies spanning from molecules to tissues
have revealed complex regulatory mechanisms that fine-tune
cardiac contraction, in which myosin not only generates po-
wer output but also plays an active role in its regulation. Thus,
myosin is both shaped by and actively involved in shaping its
mechanical environment. Moreover, these studies have shown
that cardiac myosin-generated tension affects physiological
processes beyond muscle contraction. Here, we review these
novel regulatory mechanisms, as well as the roles that myosin-
based force generation and mechanotransduction play in
development and disease. We describe how key intra- and
intermolecular interactions contribute to the regulation of
myosin-based contractility and the role of mechanical forces in
tuning myosin function. We also discuss the emergence of
cardiac myosin as a drug target for diseases including heart
failure, leading to the discovery of therapeutics that directly
tune myosin contractility. Finally, we highlight some of the
outstanding questions that must be addressed to better un-
derstand myosin’s functions and regulation, and we discuss
prospects for translating these discoveries into precision
medicine therapeutics targeting contractility and
mechanotransduction.
Cardiac myosin is best known as the molecular motor that
powers heart contraction. It is a member of the myosin II
family (also known as conventional myosin), which includes
two-headed, filament-forming muscle and nonmuscle myo-
sins. Although this “conventional” myosin has been studied
for several decades, recent studies have revealed novel func-
tions and regulatory mechanisms that are anything but con-
ventional. It has become clear that cardiac myosin not only
powers heart contraction but also plays pivotal roles in
muscle regulation, development, and mechanotransduction.
Dysfunction of myosin in these processes can lead to a range
of cardiac diseases with different presentations and
prognoses.
Here, we review the complex functions and regulatory
mechanisms of cardiac myosin revealed by recent multiscale
studies. We highlight the roles played by myosin-based
contractility and mechanotransduction in supporting cardiac
development and their dysfunction in disease. Finally, we
discuss cardiac myosin as an emerging target for novel ther-
apeutics developed for heart diseases.
Cardiac myosin structure
Cardiac myosin is a heterohexameric protein consisting of
two myosin heavy chains (MHCs), two regulatory light chains
(RLCs), and two essential light chains (ELCs) (Fig. 1A). Re-
gions of myosin are frequently labeled by names derived from
proteolytic fragmentation, where limited proteolysis with
chymotrypsin yields heavy meromyosin (HMM) and light
meromyosin (LMM) fragments. HMM can further be diges-
ted to yield subfragment-1 (S1), monomeric myosin heads
containing either one or two of the light chains depending on
the protease used, and subfragment-2 (S2). Each MHC S1
head contains a nucleotide-binding pocket and an actin-
binding interface. The head domain is followed by the light
chain-binding domain, a single alpha helix that amplifies
small conformational changes in the nucleotide-binding site
into a large displacement known as the working stroke or
power stroke. The light chain-binding domain is mechanically
reinforced by an ELC and an RLC, where the ELC is proximal
to the head domain. The light chain-binding domain is fol-
lowed by the S2 region, which helps to dimerize the two
MHCs. The flexibility and length of the S2 region may impact
the unloaded shortening velocity of muscle (that is, the speed
at which the muscle length decreases in the absence of
external force) by imposing a drag load on filaments moving
at high velocities (1–3). As we will discuss later, S2 also plays
an important role in myosin autoinhibition. The S2 region is
followed by the LMM fragment (also known as the tail),
which contains a large coiled-coil tail domain that interacts
with tails of other myosin molecules to form the bipolar thick
filament.
While many muscle and nonmuscle myosin isoforms have
been crystallized (4, 5), it was not until 2015 that the first
crystal structure of the cardiac myosin motor domain was
solved (6). The myosin shares many of the critical structural
elements common to myosins including loops involved in* For correspondence: Michael J. Greenberg, greenberg@wustl.edu.
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nucleotide binding (e.g., P-loop, switch-1, and switch-2), actin
binding (e.g., the cardiomyopathy loop, loop 2, loop 4, and the
helix-loop-helix domain), and mechanical elements (e.g., relay
helix, SH1 and SH2 helices, and converter domain) (Fig. 1B).
The reader is referred to excellent reviews on myosin structure
and function for additional details on the role of these ele-
ments in mechanochemical coupling (7, 8). Crystal structures
of the cardiac myosin motor domain in both the pre-power
stroke and post-power stroke conformations revealed a fold
very similar to other myosin isoforms (6, 9, 10). This obser-
vation led to the question of how different myosin motors with
high degrees of structural conservation can have biochemical
properties (e.g., ADP release rate, duty ratio) that vary by or-
ders of magnitude. A recent molecular dynamics study
demonstrated that small changes in myosin sequence can give
rise to changes in global protein fluctuations, and that different
conformational ensembles explored by a myosin motor in
solution correlate with functionally relevant biochemical
properties (11). Moreover, recent technological advances in
the field of cryo-electron microscopy enabled the
determination of a structure of cardiac myosin bound to actin
(12). This structure revealed that several disordered loops in
the myosin structure are stabilized in the actomyosin complex,
including several residues frequently mutated in human
disease.
Cardiac muscle contraction
The fundamental contractile unit in cardiac muscle is the
sarcomere, which consists of interdigitated thin and thick fil-
aments that lie between α-actinin-containing structures called
Z-discs (Fig. 2). Regions of the sarcomere are named for their
appearance as light and dark bands in electron micrographs of
muscle: myosin is localized to the dark A-band, whereas the
light band that contains actin is called the I-band. Myosin-
containing thick filaments are organized into A-bands by
myomesin at the M-line and anchored to the Z-discs by titin.
In the C-zone of the sarcomere, cardiac myosin interacts with
cardiac myosin-binding protein C (cMyBP-C). cMyBP-C is
anchored to the thick filament by its C-terminal region,
Figure 1. Cardiac myosin structure. A, schematic structure of cardiac myosin showing the regions named for proteolytic fragments heavy meromyosin
(HMM), light meromyosin (LMM), subfragment-1 (S1), and subfragment-2 (S2). Full-length myosin consists of two heavy chains (yellow and green), each
bound to an essential light chain (ELC, dark pink) and a regulatory light chain (RLC, light pink). The myosin heads (S1 region) contain the sites of ATP and
actin binding. The tails (LMM) are coiled coils that assemble into the thick filament. B, structure of the human cardiac myosin motor domain based on PDB
ID 4PA0, where the loops not resolved in the crystal structure were modeled using homology modeling. Structural domains related to the mechanical
power stroke, actin binding, and nucleotide binding to the active site are highlighted. For additional details on the structural mechanism of myosin force
generation, the reader is referred to (7).
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whereas the N-terminal region regulates muscle contraction
through its interactions with either the myosin head domain or
the thin filament. Thin filaments, consisting of actin filaments
decorated with proteins including tropomyosin and troponin,
are anchored to the Z-discs via their barbed ends. This
orientation of the actin filaments ensures that cardiac myosin,
which moves toward the barbed end of actin, will directionally
pull the Z-discs toward the center of the sarcomere, shortening
the distance between the Z-discs.
The force generated by a muscle is proportional to the
number of actin-bound myosins (termed “crossbridges”
because they bridge the thick and thin filaments) and the
average force per crossbridge. Each individual motor generates
1 to 5 pN of force (13); however, the collective motion of many
motors in the sarcomere produces higher forces. The number
of crossbridges bound to actin at a given time is the product of
the total number of available, active myosin heads, and the
duty ratio (i.e., the fraction of the biochemical cycle that a
given crossbridge remains bound to actin) (14). The power
output is the product of the shortening speed and the force. As
such, force production depends on both the kinetics of the
ATPase cycle and the mechanics of the motor. As discussed
below, these parameters can be dynamically tuned to match
the physiological loads of the body.
The actomyosin biochemical cycle
Myosin is an ATPase that utilizes energy drawn from ATP
hydrolysis to generate movement (15) (Fig. 3). Changes in the
myosin-bound nucleotide modulate the affinity of myosin for
actin (16), where the myosin and actin can either be strongly
bound (i.e., force-generating or -bearing states) or weakly
bound (i.e., actomyosin is primarily dissociated but transiently
interacting through short-lived, weak electrostatic interactions
that do not bear load) (17–19). In the absence of nucleotide,
myosin and actin are strongly bound in a rigor complex. ATP
binding to actin-bound myosin causes actomyosin dissocia-
tion. Myosin hydrolyzes ATP to ADP and inorganic phosphate
and isomerizes to the pre-power stroke conformation, where
the head is primed to generate force. Myosin then rebinds to
actin, initiating the force-generating power stroke and trig-
gering the release of inorganic phosphate. During the power
stroke, the light chain-binding domain rotates by 70,
generating a 4 nm displacement. ADP is then released and
Figure 2. Cardiac myosin integration into the sarcomere. A, diagram of the sarcomere, drawn roughly to scale. Bands and discs observed by
electron microscopy are labeled. B, cartoon showing a zoomed-in view of the sarcomere within the C-zone. Elements are drawn roughly to scale.
Myosin heads in the super relaxed state (SRX) are bound to the thick filament backbone, whereas myosin heads in the disordered relaxed state (DRX)
are freed from the backbone. C, schematic structure of myosin in the autoinhibited, interacting heads motif (IHM) associated with the SRX (left and
center) and the DRX (right). In the IHM, the blocked head (yellow) interacts with the free head (green). It has been proposed that the IHM is stabilized by
cMyBP-C (blue), where phosphorylation of cMyBP-C reduces its interaction with myosin (center). Phosphorylation of the RLC (pink) and mechanical
forces each promote the formation of the DRX; however, it is important to note that they are not required for the formation of the DRX. Note that RLC
phosphorylation can occur on either one or both of the heads.
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the light chain-binding domain rotates further to the post-
power stroke state, generating an additional 2 nm displace-
ment (20, 21) for a total displacement of 6 nm (22–26).
The transition to strong binding and the associated release
of phosphate is the slowest step in the myosin ATPase cycle
and the step associated with the largest release of free energy
(16). Actin binding accelerates the rate of phosphate release
from myosin by orders of magnitude; however, this transition
remains the rate-limiting step of the overall ATPase cycle in
the presence of actin (16). Although some structural studies
have indicated that phosphate release precedes the power
stroke (27, 28), recent optical trapping and spectroscopic
measurements suggested that the power stroke precedes
phosphate release (24, 29–31). Regardless of this order, the
primary steady-state intermediate of the ATPase cycle is a
state in which actin and myosin are dissociated and myosin is
bound to ADP and inorganic phosphate.
While the rate of actin-activated phosphate release limits
the overall ATPase cycle, other biochemical rates determine
physiologically important parameters of muscle contraction,
including the shortening speed, force, and power output. The
unloaded shortening rate of a muscle is generally thought to be
limited by the rate of actomyosin crossbridge detachment (32,
33). Therefore, the rate of ADP release sets the rate of
unloaded shortening, since this rate limits crossbridge
detachment at physiologically relevant ATP concentrations
(34). The speed is also proportional to the size of the myosin
working stroke (32), which can be altered by disease-causing
mutations (21). It should be noted that other models of
muscle contraction have been proposed, including a recent
model where the speed depends on both attachment and
detachment kinetics (2). In this model, the speed is related to
the length and flexibility of the S2 linker as well as the myosin
step size.
Figure 3. The myosin mechanochemical cycle and its regulation. For simplicity, only one myosin head is shown. In the super relaxed state (SRX, blue
shaded box), myosin is autoinhibited. Force and RLC phosphorylation each promote the adoption of the disordered relaxed state (DRX). The thin filament
can lie in the blocked, closed, or open states, where switching between states depends on calcium and myosin binding. In the open state, myosin can bind
to and detach from the thin filament in a nucleotide-dependent manner. Bound and detached states are indicated by yellow and red shading, respectively.
Force-dependent steps are indicated by red arrows. Mechanical substeps of the working stroke and structural states (pre-power stroke and post-power
stroke) are labeled.
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Regulation of actomyosin-based force generation
While the basics of the myosin biochemical cycle have been
understood since the 1970s (16), our understanding of the
regulation of cardiac myosin has advanced greatly in the past
few years. These advances have been made possible by mul-
tiscale studies of increasing complexity and several techno-
logical innovations. These studies have given a more nuanced
understanding of how the heart fine-tunes its power output
over various length and temporal scales, identified new
mechanisms of disease pathogenesis, and provided new ave-
nues for the development of therapeutics for heart diseases.
Moreover, they identify mechanisms by which cardiac myosin
not only generates cardiac power output, but also plays a
critical role in its regulation.
Regulation of accessibility of myosin-binding sites on actin
Cardiac contraction is regulated from beat-to-beat by cal-
cium (Ca2+). The calcium-dependent interactions between
the thick and thin filaments are regulated by troponin and
tropomyosin (Figs. 2 and 3) (35, 36). During diastole, the
relaxation phase of the cardiac cycle, intracellular calcium
levels are low and tropomyosin adopts the blocked state,
sterically blocking myosin-binding sites along the thin fila-
ment and preventing contraction. During myocyte activation,
intracellular cytoplasmic calcium levels rise, and calcium
binding to troponin C causes tropomyosin to move to the
closed position on the thin filament, partially exposing the
myosin-binding interface on actin. Tropomyosin can then
move into the open position, in which the myosin-binding
site is fully exposed. The binding of one myosin uncovers
adjacent myosin-binding sites on actin that were obscured by
tropomyosin, resulting in cooperative activation of the thin
filament. Myosin generates force during systole, the
contraction phase of the cardiac cycle, until cytoplasmic
calcium levels drop, leading to deactivation of the thin fila-
ment. Thus, the processes of muscle activation and relaxation
depend on both calcium and myosin binding to the thin
filament (35, 37–39).
Recent studies have shown that myosin-binding protein-C
(cMyBP-C) may play a role in tuning thin filament activation.
The reader is referred to a recent review on cMyBP-C for more
details on its structure and function (40). The N-terminal re-
gion of cMyBP-C can bind to the thin filament (41), shifting
tropomyosin into the open position (42–44). This shift reduces
the energy barrier for myosin strong binding, enabling force
generation at lower levels of calcium (45). This is consistent
with muscle fiber studies using cMyBP-C knockout mice (46)
and mice lacking the N-terminal region of cMyBP-C (47),
which each showed reduced thin filament activation in
response to calcium. Moreover, elegant experiments using
transgenic mice expressing an engineered construct of
cMyBP-C with an N-terminal region that can be cleaved and
exchanged with a recombinant cMyBP-C construct showed
that removal of the N-terminal region causes spontaneous
oscillatory contractions (47). These spontaneous oscillations
were damped when the N-terminal region was added back to
the cMyBP-C. Based on these results, it was proposed that
cMyBP-C binding to the thin filament helps to maintain
tropomyosin in the open position, preventing relaxation of the
muscle before calcium levels drop (48). This activation can be
dynamically tuned. Upon β-adrenergic stimulation, protein
kinase A (PKA) phosphorylates cMyBP-C, reducing the
binding of cMyBP-C to the thin filament and tuning the level
of thin filament activation (49, 50). We speculate that myosin-
induced movement of tropomyosin along the thin filament
may also increase the binding of cMyBP-C to the thin filament,
since it exposes cMyBP-C-binding sites along actin.
Regulation of the number of force-generating myosin heads
Although the regulation of molecular motors by auto-
inhibition has been recognized for a while (51–56), even in the
context of myosin II (57–61), recognition of the functional
importance of autoinhibition in striated muscle myosin has
emerged more recently. Key evidence of thick filament-based
regulation of striated muscle was provided by measurements
in Roger Cooke’s lab of the single turnover rate of ATP in
relaxed skeletal muscle (i.e., at low calcium) using a fluores-
cent ATP analog, Mant-ATP (62). They observed biphasic
turnover kinetics, with one rate similar to that of ATP turn-
over of myosin S1 in solution in the absence of actin
(0.05 s−1) and a much slower rate (0.004 s−1). They proposed
that the fast and slow rates represent populations of myosins
in a disordered relaxed state (DRX) and super relaxed state
(SRX), respectively (62, 63). The SRX was later observed in
cardiac muscle (64).
It has been proposed that the biochemical SRX corresponds
with an autoinhibited structural state observed in cryo-
electron microscopy reconstructions of thick filaments from
cardiac muscle, smooth muscle, and tarantula skeletal muscle
(59, 65–67). In this structure, the myosin heads fold back
toward the S2 region to form an asymmetric structure known
as the interacting heads motif (IHM) (Fig. 2). One head,
dubbed the blocked head, is locked in the pre-power stroke
state, and it interacts with its own S2 region. The primary
head–head interaction site, which is adjacent to the actin-
binding region of the blocked head, interacts with the con-
verter domain of the other, free head, locking both heads in
the autoinhibited state (68, 69). Interestingly, this structure
has many similarities to the autoinhibited state seen in iso-
lated, full-length smooth muscle and nonmuscle myosin II
molecules (58, 60, 61).
Several pieces of evidence connect the biochemical SRX and
the IHM structural state. X-ray diffraction studies of intact
cardiac muscle fibers demonstrated a correspondence between
the fraction of ordered myosin heads along the thick filament
backbone and the fraction of heads in the SRX measured
biochemically (68). Negative stain electron microscopy of
myosin motors also revealed a correlation between the fraction
of heads in the SRX and the fraction of heads that form an
autoinhibited structure. In addition, small-molecule
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compounds that altered the biochemical SRX induced a
similar change in the fraction of heads in the autoinhibited
state. Collectively, these data suggest a correspondence be-
tween the SRX and the IHM.
The IHM is likely stabilized by interactions between
myosin and cMyBP-C (70). Spudich noted that the cardiac
myosin head has a large, flat region enriched with charged
residues that is likely involved in forming protein–protein
interactions, which he dubbed the “mesa domain” (69).
Many mutations that cause genetic cardiomyopathies are
found on the mesa domain (71). Part of the mesa forms the
interface of the IHM; however, another part of this region is
exposed. It was proposed that the exposed part of the mesa
interacts with cMyBP-C in the thick filament. Deletion of
cMyBP-C reduces the formation of the SRX (72). Moreover, it
was shown that an N-terminal fragment of cMyBP-C can
bind to myosin in solution, and that this binding promotes
the formation of the biochemical SRX (70). Phosphorylation
of cMyBP-C by PKA upon β-adrenergic stimulation decreases
the interactions between cMyBP-C and myosin, destabilizing
the SRX (73).
The fraction of myosins in the SRX can be dynamically
modulated by mechanisms that decrease the fraction of
myosin heads in the SRX, increasing the number of myosin
heads available to generate force (Figs. 2 and 3). For example,
RLC phosphorylation by myosin light chain kinase is essential
for the activation of smooth muscle and nonmuscle myosin II
isoforms, but not striated muscle myosins. In the heart, cardiac
contraction is modulated through a large gradient of RLC
phosphorylation between layers of the heart that has been
proposed to play a role in generating torque during blood
ejection (74). X-ray diffraction studies demonstrated that RLC
phosphorylation causes the myosin heads to move closer to the
thin filament, and that this modulates the kinetics of muscle
contraction (75–77). Recent studies demonstrated that RLC
phosphorylation destabilizes the SRX, increasing the popula-
tion of the DRX state (70).
The fraction of myosin heads in the SRX can also be
regulated by mechanical force (78). Recent studies using
intact muscle fibers demonstrated that stretching cardiac
muscle causes an increase in the fraction of available heads
(79, 80). This mechanosensitive release of myosin motors in
the SRX from the thick filament backbone might enable the
muscle to quickly and dynamically regulate the fraction of
heads in the SRX during times of increased workload
(80, 81). The force-dependent decrease in the SRX popula-
tion results in generation of larger forces by myofilaments at
longer sarcomere lengths, which, together with incompletely
understood thin filament-based mechanisms, underlies
length-dependent activation in cardiomyocytes (79–84).
Length-dependent activation contributes to the tissue-level
relationship between the extent of ventricular filling and
the strength of cardiac contraction, known as the Frank–
Starling law of the heart (85). The force-induced destabili-
zation of the SRX can only be observed in the context of
myosin filaments, emphasizing the importance of multiscale
studies to fully understand the mechanisms intrinsic to
myosin that help to regulate and fine-tune the force and
power output of muscle.
Regulation of myosin motor function by mechanical forces
Mechanical forces that assist or resist the myosin power
stroke can affect the rates of biochemical transitions, thereby
tuning muscle force production and power output. This me-
chanical regulation tunes the myosin contractility on very fast
timescales (i.e., from power stroke to power stroke). This was
first recognized in pioneering work by Hill and Fenn, who
noted that the heat released during muscle shortening was
greater during unloaded shortening than under high tension
(86, 87). In the case of muscle myosins, muscle fiber and op-
tical trapping experiments have revealed that there are mul-
tiple force-sensitive transitions (Fig. 3) (20, 24, 88, 89). As
described earlier, the unloaded shortening speed of muscle is
limited by the rate of ADP release, the transition that limits
actomyosin dissociation at physiological ATP concentrations
(20, 34, 90). In the presence of loads that oppose the myosin
working stroke, the rate of ADP release slows, slowing the rate
of muscle contraction (20, 25, 91).
In addition to slowing ADP release, mechanical forces can
also modulate the number of force-generating crossbridges by
affecting both the isomerization to the strong binding state
and subsequent phosphate release (24, 88). Recent experi-
ments using an ultrafast optical trap demonstrated that
increasing loads that either resist or assist the power stroke
can increase the rate of actomyosin dissociation before
myosin isomerization to the strong binding state (Fig. 3) (24).
This pre-power stroke detachment occurs at rates that are an
order of magnitude faster than the rate of ADP release.
Assisting and resisting forces have asymmetric effects on this
dissociation rate due to the stereospecific interactions
required for myosin cleft closure. Moreover, forces that resist
the power stroke can also increase the probability of phos-
phate rebinding and reversal of the power stroke. Taken
together, these three force-dependent pathways (slowing of
ADP release, preventing strong binding, and reversing the
power stroke) tune the speed, force, and power generated by
the muscle.
Regulation by transcriptional regulation of isoform expression
The contraction of cardiac myosin can be regulated tran-
scriptionally by differential expression of MHC, ELC, and RLC
subunits. In the adult human heart, the primary ventricular
isoforms are MYH7 MHC (β-cardiac myosin), MYL3 ELC, and
MYL2 RLC, whereas the primary atrial isoforms are MYH6
MHC (α-cardiac myosin), MYL4 ELC, and MYL7 RLC (92).
While these are the primary isoforms expressed, multiple
isoforms are expressed within a ventricle, and heteromolecules
(e.g., a myosin dimer made of oneMYH7MHC and oneMYH6
MHC) have been observed (93). Evidence from murine hearts
showed that the expression of MYH6 and MYH7 MHCs in the
ventricles can vary spatially with enrichment in substructures
within the heart (94). The exact composition of MHC, RLC,
and ELC can tune the kinetics and mechanics of the myosin.
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For example, MYH7 MHC has a significantly slower ADP
release rate and unloaded shortening speed compared with
MYH6 MHC (95, 96), but MYH7 motors can generate a larger
ensemble force (97). Similarly, the size of the working stroke of
muscle myosins depends on the ELC isoform (98).
The expression of myosin isoforms changes over time
during development and disease. For example, in the human
heart, the fraction of MYH7 MHC expressed in both the atria
and ventricles increases between the fetal and adult hearts (99).
The fraction of MYH7 MHC also changes during disease. In
the ventricle, MYH7 MHC expression increases from 93% in
the healthy heart to 100% MYH7 MHC in the failing heart
(100, 101), and the amount of MYH7 MHC in the atria in-
creases from 14% in the healthy heart to 50% in the failing
heart. Therefore, changes in the expression of different myosin
isoforms play an important role in modulating cardiac
contractility during long-term cardiac remodeling associated
with development and disease.
Myosin mechanosensing
Beyond its role generating cellular tension, cardiac myosin is
part of the machinery necessary for sensing and transducing
molecular forces. Thus, disrupted cellular tension affects
cellular processes beyond muscle contraction. For example,
myosin-generated tension is required to support sarcomere
organization in cardiomyocytes, although the respective roles
of cardiac and nonmuscle myosins in sarcomere assembly and
maintenance remain somewhat controversial (102, 103).
Treatment with blebbistatin, which disrupts myosin-driven
contraction, leads to loss of sarcomere content in human
induced pluripotent stem cell–derived cardiomyocytes
(hiPSC-CMs) (102). Milder disruptions to myosin-generated
force by pathogenic mutations in sarcomeric proteins can
lead to sarcomeric remodeling (104, 105).
Myosin mechanosensing also plays a direct role in devel-
opment. The stiffness of cardiac tissue increases during em-
bryonic development, where adult tissue is 10× stiffer than
the embryonic heart (106). The myosin-driven spontaneous
contraction of cardiomyocytes isolated from embryonic chick
hearts is optimized on substrate stiffnesses similar to that of
embryonic heart tissues (107). Alteration of tissue elasticity via
treatment of isolated embryonic heart tubes with collagenase
(to soften) or a cross-linking enzyme (to stiffen) each impaired
spontaneous beating, demonstrating that myosin contractile
function is exquisitely matched to matrix elasticity (107).
Moreover, myosin contractility plays a role in feedback loops
of signaling pathways driving the cell cycle in embryonic hearts
(108). Therefore, perturbations that affect myosin function can
effect changes beyond force generation.
Altered myosin contractility leads to disease
Given its central role in driving circulation, functional car-
diac myosin is essential for life. Actomyosin function can be
modulated by many factors, including posttranslational mod-
ifications (109–112) and genetic mutations. A large number of
mutations in cardiac myosin genes, including both the heavy
and light chains, are associated with human disease, including
familial cardiomyopathies (hypertrophic, dilated, and restric-
tive) (113–115), left ventricular noncompaction (116), skeletal
myopathies (117), developmental defects (e.g., atrial septal
defects) (118), and electrophysiological disorders (e.g., sick si-
nus syndrome) (119). The majority of these pathogenic mu-
tations are point mutations that change myosin’s properties
without rendering it nonfunctional, since major changes are
incompatible with life. Interestingly, different mutations within
the same gene can lead to different diseases, and the
complexity of the resulting disorders clearly demonstrates that
these mutations affect processes beyond just force generation.
The variety of diseases caused by myosin mutations suggests
that the context and specific effects of the mutation on mo-
lecular function are important for both the disease patho-
genesis and progression (120). Below, we discuss two different
classes of diseases caused by mutations in cardiac myosin.
Familial cardiomyopathies
Familial cardiomyopathies, leading causes of sudden cardiac
death and heart failure in young people, are caused by muta-
tions in several genes, including those encoding myosin heavy
chain (MYH7), ELC, and RLC. MYH7 mutations were the first
identified genetic causes of familial hypertrophic cardiomy-
opathy (HCM) (121, 122), a heart disease characterized by left
ventricular hypertrophy and impaired cardiac relaxation (115).
Since then, it has been shown that mutations in cardiac myosin
(MHC, RLC, and ELC) (123) can also cause dilated cardio-
myopathy (DCM), which involves left ventricular dilation and
impaired systolic function (124).
A central challenge for the field is to distinguish primary
drivers of disease from downstream and/or secondary effects
(120). This is particularly challenging since these disorders are
protean in nature, where different pathways are activated over
the course of these progressive diseases (often years to de-
cades). A mechanistic understanding is important for the
design of potential precision medicine therapeutics. The
involvement of mutations in myosin and other sarcomeric
proteins (125, 126) in HCM and DCM suggests altered cardiac
contractility as a pathogenic mechanism. The integral of ten-
sion development over time in both mice and hiPSC-CMs
predicted whether a given mutation leads to hypertrophic or
dilated cardiomyopathy better than measurements of calcium
handling (127), where increased contractility is associated with
HCM and decreased contractility with DCM. Importantly,
modulation of the tension integral can prevent pathogenic
remodeling (127, 128). Moreover, recent studies from our lab
used a computational model of cardiac contraction (129) to
show that altered thin filament regulation can predict changes
in cardiac contractility that are consistent with those seen in
cardiomyocytes (105).
Due to the inherent complexity of the disease pathogenesis,
there has been a strong push to develop model systems that
recapitulate the disease phenotype and enable functional
studies of human disease-causing mutations in vitro. Excellent
transgenic mouse studies have provided insights into the
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disease pathogenesis; however, they have the limitation that
mouse ventricles express primarily MYH6 MHC, not MYH7
MHC like in the human heart (130). Due to functional differ-
ences between MYH6 and MYH7 MHCs, the presentation and
biophysical defects associated with a given mutation can vary
depending on the MHC backbone (131–136). AlthoughMYH7
MHC protein can be obtained from patient biopsy samples,
there are several associated challenges, including small quanti-
ties and unknown ratios of mutant to wild-type protein, which
can lead to inconsistent results (137, 138). Thus, one of the
principal challenges to studying human MYH7 mutations
in vitro has been the lack of recombinant expression system.
While many myosin isoforms, including nonmuscle myosin-II
and smooth muscle myosin, can be expressed using the bacu-
lovirus/Sf9 system, striated muscle myosins cannot due to the
lack ofmuscle-specific chaperones (139–141). The recombinant
expression of striated muscle myosins in murine myoblast cells
(C2C12) was a major step forward that enabled the production
of sufficient quantities of soluble recombinant protein for
functional and structural studies (6, 95, 142).
Studies using recombinant human cardiac myosin revealed
that cardiomyopathy-associated mutations can directly affect
contractility at the level of individual motors (143, 144). Mu-
tations that cause HCM typically increase molecular contrac-
tility, whereas DCM-causing mutations decrease contractility
(123). However, some of these effects only become apparent
when looking at reconstituted systems of increasing
complexity. For example, studies using recombinant R403Q
cardiac myosin in the MYH7 MHC backbone observed
increased velocity in an unregulated in vitro motility assay;
however, the difference in velocity disappeared when regulated
thin filaments were used (145). Furthermore, the intrinsic
force generated by an R403Q myosin motor was lower than
that generated by wild-type myosin, and altogether the results
were consistent with reduced contractile function for R403Q
motors (145). This might have suggested that hyper-
contractility in HCM caused by R403Q can be a secondary
compensatory mechanism to counteract reduced myosin
function, rather than a primary driver of disease. However, it
was later demonstrated that the R403Q mutation destabilizes
the myosin SRX, leading to increased contractility (70, 146).
Furthermore, the R403Q mutation ablates binding of cMyBP-
C, which promotes adoption of the SRX in wild-type myosin
(146). This mechanism of increased contractility via an in-
crease in the number of available myosin heads, regardless of
the intrinsic contractility of each myosin head, has also been
demonstrated for several other HCM-associated mutations in
cardiac myosin (146–149). In contrast, DCM-causing muta-
tions tend to directly affect the force-generating capacity of
individual myosin motors (150, 151). That said, the effects of a
given mutation on protein function are often complex and may
be best described by a combination of effects rather than a
single mechanism. However, the grouping of mutations by
common effects is useful for our fundamental understanding
of disease pathogenesis as well as to aid the development of
novel therapeutics that target specific disease mechanisms, as
described in a recent review (120) and discussed below.
Atrial septal defect
Mutations in MYH6 MHC, the primary atrial myosin iso-
form, can lead to atrial septal defect, a congenital heart mal-
formation (118, 152, 153). During development, MYH6 is
required for the proper formation of the atrial septum, the wall
between the two atrial chambers (118). Mutations in MYH6
that cause atrial septal defect appear to affect the interaction
between the myosin heavy chain and the RLC (118) or between
myosin and actin (152, 153). In contrast to cardiomyopathies,
which can take decades to develop into symptomatic disease
despite the presence of the mutation since birth, atrial septal
defects are congenital heart defects. This is consistent with
actomyosin-generated tension during development driving
cellular function and organization.
Altered contractility results in downstream
mechanobiological dysfunction
Although pathogenic point mutations in cardiac myosin can
affect cardiac contraction, changes in contractility in isolation
are insufficient to explain the disease pathogenesis and
complexity of presentation. At the molecular scale, defects in
function due to pathogenic mutations are usually subtle, which
is not surprising because major changes would be incompat-
ible with life. In the case of familial cardiomyopathies, the
mutant protein is expressed over the entire lifetime of the
patient; however, pathological cardiac remodeling often does
not occur until adolescence or later (154). There is evidence
that genotype-positive patients show alterations in cardiac
contractility before the development of pathogenic remodeling
and symptomatic disease (155, 156). As such, mutation-
induced changes in myosin contractility can be the initial in-
sults that drive the early disease pathogenesis, leading to the
activation of adaptive pathways that initially normalize cardiac
function, but eventually transition to maladaptive remodeling.
These maladaptive responses drive the disease symptoms and
progression. Altered calcium handling (157), increased fibrosis
(158), myofibrillar disarray (159), aberrant electrophysiology
(160), and cellular hypertrophy (161) are all downstream
consequences of the initial insult of altered contractility.
Similarly, in the case of atrial-septal defects caused by
MYH6 mutations, changes in myosin-based force production
affect cardiac development. In this case, the disease phenotype
is likely due to changes in the interactions between cells, not to
changes in ejection fraction. The alteration of cellular function,
gene expression, and tissue morphology by mutation-induced
changes in myosin-based tension generation highlight the
important role that cardiac myosin plays in mechanobiological
signaling pathways.
Pathogenic mutations in myosin can also drive changes in
tissue mechanics. Altered tissue stiffness plays a role in heart
failure, where the prevalence of detyrosinated microtubules
results in increased cardiomyocyte stiffness and impaired
contractility (162). Higher levels of microtubule detyrosination
were found in tissue isolated from HCM patients with sarco-
meric mutations compared with sarcomere mutation-negative
HCM patients, suggesting that microtubule detyrosination
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plays a role in the downstream pathogenesis of HCM caused
by mutations in sarcomeric proteins (163).
Finally, it is important to note that disrupted force genera-
tion can affect processes beyond the myocyte. An example of
this is the activation of the fibroblast-to-myofibroblast transi-
tion by mechanical tension (164). Multiple stimuli that alter
cardiac contraction (e.g., hypertension, mutations, aortic ste-
nosis) can drive the development of hypertrophy and myofi-
broblast activation. Myofibroblasts secrete large amounts of
extracellular matrix, contributing to fibrosis frequently seen
with cardiomyopathies (165). Therefore, when considering the
downstream effects of myosin mutations on disease, it is
important to consider that these effects can be long-lasting and
extend beyond the myocyte.
Small molecules that target myosin contractility
Due to its role in driving and regulating heart contraction, as
well as its dysfunction in disease, cardiac myosin has emerged
as a drug target. There are several myosin-binding compounds
in development and in clinical trials that target cardiac
contractility either directly or through its regulatory mecha-
nisms (Fig. 4).
Activators of cardiac contraction for systolic dysfunction
There are several conditions that can lead to heart failure
with reduced systolic function, including coronary artery dis-
ease, myocardial infarction, myocarditis, and dilated cardio-
myopathy (166). The majority of current therapeutics alleviate
symptoms and target prevention of additional adverse
remodeling; however, the transplant-free survival rate is low.
Moreover, many of these therapeutics show limited efficacy in
pediatric heart failure (167). Therefore, there is an outstanding
clinical need to develop therapeutics to improve outcomes for
patients, or patient subpopulations, with systolic heart failure.
Omecamtiv mecarbil (OM) was the first small-molecule
therapy targeting cardiac myosin (168). It was discovered in
a high-throughput screen for compounds that increase the
actin-activated ATPase rate of cardiac myosin by increasing
the rates of ATP hydrolysis and phosphate release. OM binds
near the myosin converter domain, and therefore, exerts its
effects on the nucleotide-binding pocket allosterically. Studies
in isolated myocytes showed improved systolic function
without changes to the calcium transient. Moreover, the recent
GALACTIC-HF study demonstrated improved outcomes of
patients with heart failure in phase 3 clinical trials (169).
Given its effects on the myosin ATPase rate, OM was
originally proposed to act as a myosin activator; however,
further studies revealed that its biophysical mechanism of
action is more complicated than originally realized. While OM
increases the actin-activated ATPase rate of unregulated thin
filaments, it acts as an inhibitor when examined using regu-
lated thin filaments at high calcium (170). Moreover, OM
causes a dramatic 20-fold reduction in myosin’s motility rate,
suggesting a complex mechanism of action (171). Recent op-
tical trapping and transient kinetics experiments demonstrated
that OM causes cardiac myosin to enter a noncanonical
pathway with a long-lived strong binding state (25, 172).
Moreover, OM-bound myosins do not generate a productive
working stroke (25, 173). Thus, OM uncouples the kinetics
and mechanics of the working stroke of individual motors,
leading to reduced motile function.
Given that OM appears to reduce actomyosin detachment
kinetics and inhibit the working stroke, how does it increase
cardiac contractility in myocytes and patients? These seem-
ingly contradictory results could be resolved by two nonex-
clusive mechanisms revealed by looking at systems of
increasing complexity. The first mechanism involves thin
filament activation. As mentioned earlier, thin filament acti-
vation can be accomplished by both calcium and myosin
Figure 4. Pharmacological agents targeting cardiac myosin. Chemical structures, mechanisms, and current clinical trial status of myosin-targeting drugs
that treat systolic (blue shading) or diastolic (red shading) dysfunction.
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binding. By increasing the lifetime of the strongly bound state
of cardiac myosin, OM keeps the thin filament in an activated
state, leading to increased contractility (25). This result is
supported by studies from muscle fibers showing that OM is
most effective over a narrow range of dosages (174). At low
OM concentrations, OM-bound crossbridges activate the thin
filament while crossbridges without OM continue to power
contraction, leading to increased force production. At higher
concentrations of OM, the fraction of OM-bound unproduc-
tive crossbridges increases, reducing the force production. In
this context, OM is better characterized as a thin filament
activator rather than a myosin activator. In the second
mechanism, OM decreases the fraction of myosin heads in the
SRX, which increases force production by the muscle by
increasing the number of available heads (175). These two
mechanisms of OM action, thin filament activation and SRX
destabilization, combine to increase cardiac contraction.
The effects of OM could be specific to mutations. An
elegant example of this was the demonstration that despite
suppressing the working stroke of wild-type myosin, OM
rescues the reduced working stroke of myosin carrying the
R712L mutation (21). This surprising finding was suggested to
result from OM binding to the post-power stroke state of
R712L myosin rather than the pre-power stroke state, high-
lighting the complexity of the therapeutic mechanism of OM
and of myosin force generation more broadly. It also raises the
possibility that OM may work for some mutations better than
others, highlighting the importance of precision medicine
approaches.
Recently, a new small-molecule compound, danicamtiv, was
discovered as a myosin activator (176). While the details about
this compound are still sparse, it appears to work by increasing
the myosin ATP turnover rate, improving systolic performance
without affecting diastolic tension (176, 177). Danicamtiv is
currently in phase 2 clinical trials (177).
Another intriguing potential therapy for systolic heart fail-
ure is the use of deoxy-ATP (dATP) (178). In contrast to
OM and danicamtiv, which were identified in high-throughput
screens of small molecules that alter myosin contractility,
dATP is a naturally occurring ATP analog. dATP binds to the
myosin ATPase-binding site, where it can compete with the
binding of ATP. The steady-state maximum actin-activated
ATPase rate of myosin is higher for dATP than for
ATP (178, 179). In contrast to OM, dATP increases the
unloaded shortening velocity without affecting the isometric
tension in muscle fibers (178). Although dATP binds to the
myosin nucleotide-binding site, the effects of the drug on the
structural dynamics of actomyosin are more subtle than
initially thought. Molecular dynamics simulations revealed
that binding of dADP and Pi, the hydrolysis products of dATP,
induces allosteric changes in the myosin actin-binding site that
increase electrostatic interactions between myosin and actin,
enhancing the crossbridge attachment rate (180). By increasing
the attachment rate of myosin, this increases the number of
bound, force-generating crossbridges.
One interesting aspect of dATP therapy is that dATP is a
naturally occurring compound, produced by ribonucleotide
reductase. As such, its therapeutic use is not confined to
administering the compound directly to patients. Strategies to
introduce dATP into cardiomyocytes via overexpression of
ribonucleotide reductase have been described, demonstrating
the potential of cardiac-specific delivery using gene therapy
(181–183). Overexpression of dATP has been demonstrated to
improve contractility in several animal models (184–187), as
well as in human patient-derived tissue (188).
Inhibitors of cardiac contraction for HCM
As mentioned earlier, HCM is typically associated with
hypercontractility, and therefore, compounds reducing
contractility could help counteract the effects of disease-
causing mutations. Most current treatments for HCM are
palliative in nature. For patients with outflow tract obstruction,
they are treated with myectomy and drugs, which improve
hemodynamics (e.g., beta blockers, calcium channel blockers,
and disopyramide) while for nonobstructive patients, there are
no therapies (189). Recently, a new small-molecule therapy,
mavacamten (190), was identified from a high-throughput
screen for compounds that decrease myosin’s ATPase rate in
myofibrils. This compound directly and specifically binds to
cardiac myosin. X-ray diffraction, biochemical, and electron
microscopy studies have revealed that mavacamten decreases
myosin contractility by stabilizing the SRX (68). As such, it
decreases contractility by reducing the number of available
myosin heads. Mavacamten has shown promising results in
phase 3 clinical trials (191).
Summary and future outlook
Although cardiac myosin has been thoroughly studied for
decades, ongoing studies across scales of organization have
revealed new mechanisms of myosin function and dysfunction
that have enabled the development of promising therapeutic
candidates. There are still many unanswered questions and
challenges in this exciting field (Box 1). The structural and
biochemical mechanisms by which myosin senses and trans-
duces force are still largely unknown. Understanding of these
mechanisms is crucial to understand the physiological role of
cardiac myosin, as well as how dysregulation of myosin
Box 1. Outstanding questions for the field
How is entry into the SRX regulated?
What structural mechanisms are involved in force sensing by myosin
molecules and thick filaments?
Which signaling pathways are regulated by myosin mechanobiology,
and how do they become dysregulated in disease?
How do posttranslational modifications of myosin and its binding
partners tune myosin function over time during development and
disease pathogenesis?
How do different disease-causing mutations in myosin lead to activa-
tion of different downstream pathways?
Can myosin mutations be binned into groups that will positively
respond to a given therapeutic in order to improve patient outcomes
through a precision medicine approach?
How do specific mutations affect allosteric coupling within myosin, and
can this information explain why these myosin variants cause a given
disease?
What are the structural mechanisms of the new drugs that target
myosin function?
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contraction and mechanotransduction contribute to cardiac
disease. Furthermore, deeper understanding of disease mech-
anisms could guide the development of precision medicine
approaches to treat patients. Although patient-specific treat-
ments are likely unrealistic, it might be possible to bin muta-
tions into groups that will positively respond to a given
therapeutic (120). To realize the promise of this precision
medicine approach, we also need to better understand the
structural mechanisms of current and emerging drug com-
pounds that target myosin function. Future work might also
elucidate how specific mutations affect allosteric coupling
within myosin, potentially expanding our ability to target
cardiac myosin therapeutically. Addressing these gaps in our
understanding will require the development of new experi-
mental and computational methods that span scales of orga-
nization and faithfully recapitulate important aspects of
myosin contractility. This is an exciting time for the field to ask
basic science questions, with the possibility of translating these
findings into improved treatment of devastating diseases.
Author contributions—S. K. B. and M. J. G. conceptualization; S. K.
B. and M. J. G. funding acquisition; S. K. B. and M. J. G. writing—
original draft; S. K. B. and M. J. G. writing—review and editing.
Funding and additional information—This work was supported by
the National Institutes of Health (R01 HL141086 to M. J. G. and F32
HL152543 to S. K. B.) and the Children’s Discovery Institute of
Washington University and St. Louis Children’s Hospital (PM-LI-
2019-829 to M. J. G.). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health.
Conflict of interest—The authors have no conflicts of interest to
declare.
Abbreviations—The abbreviations used are: cMyBP-C, cardiac
myosin-binding protein C; DCM, dilated cardiomyopathy; DRX,
disordered relaxed state; ELC, essential light chain; HCM, hyper-
trophic cardiomyopathy; hiPSC-CM, human induced pluripotent
stem cell–derived cardiomyocyte; HMM, heavy meromyosin; IHM,
interacting heads motif; LMM, light meromyosin; MHC, myosin
heavy chain; OM, omecamtiv mecarbil; RLC, regulatory light chain;
S1, subfragment-1; S2, subfragment-2; SRX, super relaxed state.
References
1. Brizendine, R. K., Alcala, D. B., Carter, M. S., Haldeman, B. D., Face-
myer, K. C., Baker, J. E., and Cremo, C. R. (2015) Velocities of unloaded
muscle filaments are not limited by drag forces imposed by myosin
cross-bridges. Proc. Natl. Acad. Sci. U. S. A. 112, 11235–11240
2. Brizendine, R. K., Sheehy, G. G., Alcala, D. B., Novenschi, S. I., Baker, J.
E., and Cremo, C. R. (2017) A mixed-kinetic model describes unloaded
velocities of smooth, skeletal, and cardiac muscle myosin filaments
in vitro. Sci. Adv. 3, eaao2267
3. Brizendine, R. K., Anuganti, M., and Cremo, C. R. (2021) Evidence for S2
flexibility by direct visualization of quantum dot-labeled myosin heads
and rods within smooth muscle myosin filaments moving on actin
in vitro. J. Gen. Physiol. 153, e202012751
4. Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M.,
Holmes, K. C., and Milligan, R. A. (1993) Structure of the actin-
myosin complex and its implications for muscle contraction.
Science 261, 58–65
5. Rayment, I., Rypniewski, W. R., Schmidt-Bäse, K., Smith, R., Tomchick,
D. R., Benning, M. M., Winkelmann, D. A., Wesenberg, G., and Holden,
H. M. (1993) Three-dimensional structure of myosin subfragment-1: A
molecular motor. Science 261, 50–58
6. Winkelmann, D. A., Forgacs, E., Miller, M. T., and Stock, A. M. (2015)
Structural basis for drug-induced allosteric changes to human β-cardiac
myosin motor activity. Nat. Commun. 6, 7974
7. Robert-Paganin, J., Pylypenko, O., Kikuti, C., Sweeney, H. L., and Hou-
dusse, A. M. (2019) Force generation by myosin motors: A structural
perspective. Chem. Rev. 120, 5–35
8. Trivedi, D. V., Nag, S., Spudich, A., Ruppel, K. M., and Spudich, J. A.
(2020) The myosin family of mechanoenzymes: From mechanisms to
therapeutic approaches. Annu. Rev. Biochem. 89, 667–693
9. Robert-Paganin, J., Auguin, D., and Houdusse, A. M. (2018) Hyper-
trophic cardiomyopathy disease results from disparate impairments
of cardiac myosin function and auto-inhibition. Nat. Commun. 9,
4019
10. Planelles-Herrero, V. J., Hartman, J. J., Robert-Paganin, J., Malik, F. I.,
and Houdusse, A. M. (2017) Mechanistic and structural basis for acti-
vation of cardiac myosin force production by omecamtiv mecarbil. Nat.
Commun. 8, 190
11. Porter, J. R., Meller, A., Zimmerman, M. I., Greenberg, M. J., and
Bowman, G. R. (2020) Conformational distributions of isolated myosin
motor domains encode their mechanochemical properties. Elife 9,
e55132
12. Risi, C. M., Schäfer, L. U., Belknap, B., Pepper, I., White, H. D.,
Schröder, G. F., and Galkin, V. E. (2021) High-resolution cryo-EM
structure of the cardiac actomyosin complex. Structure 29, 50–60
13. Finer, J. T., Simmons, R. M., and Spudich, J. A. (1994) Single myosin
molecule mechanics: Piconewton forces and nanometre steps. Nature
368, 113–119
14. Spudich, J. A. (2014) Hypertrophic and dilated cardiomyopathy: Four
decades of basic research on muscle lead to potential therapeutic ap-
proaches to these devastating genetic diseases. Biophys. J. 106, 1236–
1249
15. De La Cruz, E. M., and Ostap, E. M. (2004) Relating biochemistry and
function in the myosin superfamily. Curr. Opin. Cell Biol. 16, 61–67
16. Lymn, R. W., and Taylor, E. W. (1971) Mechanism of adenosine
triphosphate hydrolysis by actomyosin. Biochemistry 10, 4617–4624
17. Geeves, M. A., Goody, R. S., and Gutfreund, H. (1984) Kinetics of acto-
S1 interaction as a guide to a model for the crossbridge cycle. J. Muscle
Res. Cell Motil. 5, 351–361
18. Geeves, M. A., and Jeffries, T. E. (1988) The effect of nucleotide upon a
specific isomerization of actomyosin subfragment 1. Biochem. J. 256,
41–46
19. Coates, J. H., Criddle, A. H., and Geeves, M. A. (1985) Pressure-relax-
ation studies of pyrene-labelled actin and myosin subfragment 1 from
rabbit skeletal muscle. Evidence for two states of acto-subfragment 1.
Biochem. J. 232, 351–356
20. Greenberg, M. J., Shuman, H., and Ostap, E. M. (2014) Inherent force-
dependent properties of β-cardiac myosin contribute to the force-
velocity relationship of cardiac muscle. Biophys. J. 107, L41–L44
21. Snoberger, A., Barua, B., Atherton, J. L., Shuman, H., Forgacs, E.,
Goldman, Y. E., Winkelmann, D. A., and Ostap, E. M. (2021) Myosin
with hypertrophic cardiac mutation R712L has a decreased working
stroke which is rescued by omecamtiv mecarbil. Elife 10, e63691
22. Palmiter, K. A., Tyska, M. J., Dupuis, D. E., Alpert, N. R., and Warshaw,
D. M. (1999) Kinetic differences at the single molecule level account for
the functional diversity of rabbit cardiac myosin isoforms. J. Physiol. 519,
669–678
23. Sugiura, S., Kobayakawa, N., Fujita, H., Yamashita, H., Momomura, S. I.,
Chaen, S., Omata, M., and Sugi, H. (1998) Comparison of unitary dis-
placements and forces between 2 cardiac myosin isoforms by the optical
trap technique: Molecular basis for cardiac adaptation. Circ. Res. 82,
1029–1034
JBC REVIEWS: Cardiac myosin in health and disease
J. Biol. Chem. (2021) 297(5) 101297 11
24. Woody, M. S., Winkelmann, D. A., Capitanio, M., Ostap, E. M., and
Goldman, Y. E. (2019) Single molecule mechanics resolves the earliest
events in force generation by cardiac myosin. Elife 8, e49266
25. Woody, M. S., Greenberg, M. J., Barua, B., Winkelmann, D. A., Gold-
man, Y. E., and Ostap, E. M. M. (2018) Positive cardiac inotrope ome-
camtiv mecarbil activates muscle despite suppressing the myosin
working stroke. Nat. Commun. 9, 3838
26. Sommese, R. F., Sung, J., Nag, S., Sutton, S., Deacon, J. C., Choe, E.,
Leinwand, L. A., Ruppel, K., and Spudich, J. A. (2013) Molecular con-
sequences of the R453C hypertrophic cardiomyopathy mutation on
human β-cardiac myosin motor function. Proc. Natl. Acad. Sci. U. S. A.
110, 12607–12612
27. Llinas, P., Isabet, T., Song, L., Ropars, V., Zong, B., Benisty, H., Sirigu, S.,
Morris, C., Kikuti, C., Safer, D., Sweeney, H. L., and Houdusse, A. M.
(2015) How actin initiates the motor activity of myosin. Dev. Cell 33,
401–412
28. Houdusse, A. M., and Sweeney, H. L. (2016) How myosin generates
force on actin filaments. Trends Biochem. Sci. 41, 989–997
29. Tang, W., Ge, J., Unrath, W. C., Desetty, R., and Yengo, C. M. (2021)
Cardiomyopathy mutations impact the power stroke of human cardiac
myosin. Biophys. J. 120, 2222–2236
30. Araujo, A., and Walker, J. W. (1996) Phosphate release and force gen-
eration in cardiac myocytes investigated with caged phosphate and
caged calcium. Biophys. J. 70, 2316–2326
31. Dantzig, J. A., Goldman, Y. E., Millar, N. C., Lacktis, J., and Homsher, E.
(1992) Reversal of the cross-bridge force-generating transition by pho-
togeneration of phosphate in rabbit psoas muscle fibres. J. Physiol. 451,
247–278
32. Huxley, H. E. (1990) Sliding filaments and molecular motile systems.
J. Biol. Chem. 265, 8347–8350
33. Huxley, A. F. (1957) Muscle structure and theories of contraction. Prog.
Biophys. Biophys. Chem. 7, 255–318
34. Siemankowski, R. F., Wiseman, M. O., and White, H. D. (1985) ADP
dissociation from actomyosin subfragment 1 is sufficiently slow to limit
the unloaded shortening velocity in vertebrate muscle. Proc. Natl. Acad.
Sci. U. S. A. 82, 658–662
35. McKillop, D. F., and Geeves, M. A. (1993) Regulation of the interaction
between actin and myosin subfragment 1: Evidence for three states of
the thin filament. Biophys. J. 65, 693–701
36. Lehman, W., Craig, R., and Vibert, P. (1994) Ca2+-induced tropomyosin
movement in Limulus thin filaments revealed by three-dimensional
reconstruction. Nature 368, 65–67
37. Houmeida, A., Heeley, D. H., Belknap, B., and White, H. D. (2010)
Mechanism of regulation of native cardiac muscle thin filaments by rigor
cardiac myosin-S1 and calcium. J. Biol. Chem. 285, 32760–32769
38. Desai, R., Geeves, M. A., and Kad, N. M. (2015) Using fluorescent
myosin to directly visualize cooperative activation of thin filaments.
J. Biol. Chem. 290, 1915–1925
39. Geeves, M. A., and Lehrer, S. S. (1994) Dynamics of the muscle thin
filament regulatory switch: The size of the cooperative unit. Biophys. J.
67, 273–282
40. Heling, L. W. H. J., Geeves, M. A., and Kad, N. M. (2020) MyBP-C: One
protein to govern them all. J. Muscle Res. Cell Motil. 41, 91–101
41. Rahmanseresht, S., Lee, K. H., O’Leary, T. S., McNamara, J. W.,
Sadayappan, S., Robbins, J., Warshaw, D. M., Craig, R., and Previs, M. J.
(2021) The N terminus of myosin-binding protein C extends toward
actin filaments in intact cardiac muscle. J. Gen. Physiol. 153,
e202012726
42. Mun, J. Y., Previs, M. J., Yu, H. Y., Gulick, J., Tobacman, L. S., Previs, S.
B., Robbins, J., Warshaw, D. M., and Craig, R. (2014) Myosin-binding
protein C displaces tropomyosin to activate cardiac thin filaments and
governs their speed by an independent mechanism. Proc. Natl. Acad. Sci.
U. S. A. 111, 2170–2175
43. Risi, C. M., Belknap, B., Forgacs-Lonart, E., Harris, S. P., Schröder, G. F.,
White, H. D., and Galkin, V. E. (2018) N-terminal domains of cardiac
myosin binding protein C cooperatively activate the thin filament.
Structure 26, 1604–1611
44. Inchingolo, A. V., Previs, S. B., Previs, M. J., Warshaw, D. M., and Kad,
N. M. (2019) Revealing the mechanism of how cardiac myosin-binding
protein C N-terminal fragments sensitize thin filaments for myosin
binding. Proc. Natl. Acad. Sci. U. S. A. 116, 6828–6835
45. Previs, M. J., Mun, J. Y., Michalek, A. J., Previs, S. B., Gulick, J., Robbins,
J., Warshaw, D. M., and Craig, R. (2016) Phosphorylation and calcium
antagonistically tune myosin-binding protein C’s structure and function.
Proc. Natl. Acad. Sci. U. S. A. 113, 3239–3244
46. Harris, S. P., Bartley, C. R., Hacker, T. A., McDonald, K. S., Douglas, P.
S., Greaser, M. L., Powers, P. A., and Moss, R. L. (2002) Hypertrophic
cardiomyopathy in cardiac myosin binding protein-C knockout mice.
Circ. Res. 90, 594–601
47. Napierski, N. C., Granger, K., Langlais, P. R., Moran, H. R., Strom, J.,
Touma, K., and Harris, S. P. (2020) A novel “cut and paste” method for
in situ replacement of cMYBP-C reveals a new role for cMYBP-C in the
regulation of contractile oscillations. Circ. Res. 126, 737–749
48. Harris, S. P. (2021) Making waves: A proposed new role for myosin-
binding protein C in regulating oscillatory contractions in vertebrate
striated muscle. J. Gen. Physiol. 153, e202012729
49. Kampourakis, T., Yan, Z., Gautel, M., Sun, Y. B., and Irving, M. (2014)
Myosin binding protein-C activates thin filaments and inhibits thick
filaments in heart muscle cells. Proc. Natl. Acad. Sci. U. S. A. 111,
18763–18768
50. Shaffer, J. F., Kensler, R. W., and Harris, S. P. (2009) The myosin-binding
protein C motif binds to F-actin in a phosphorylation-sensitive manner.
J. Biol. Chem. 284, 12318–12327
51. Armstrong, J. M., Krementsova, E., Michalek, A. J., Heaslip, A. T.,
Nelson, S. R., Trybus, K. M., and Warshaw, D. M. (2012) Full-length
myosin Va exhibits altered gating during processive movement on actin.
Proc. Natl. Acad. Sci. U. S. A. 109, e218–e224
52. Li, X. D., Ikebe, R., and Ikebei, M. (2005) Activation of myosin Va
function by melanophilin, a specific docking partner of myosin Va. J.
Biol. Chem. 280, 17815–17822
53. Hammond, J. W., Blasius, T. L., Soppina, V., Cai, D., and Verhey, K. J.
(2010) Autoinhibition of the kinesin-2 motor KIF17 via dual intra-
molecular mechanisms. J. Cell Biol. 189, 1013–1025
54. Coy, D. L., Hancock, W. O., Wagenbach, M., and Howard, J. (1999)
Kinesin’s tail domain is an inhibitory regulator of the motor domain.
Nat. Cell Biol. 1, 288–292
55. Friedman, D. S., and Vale, R. D. (1999) Single-molecule analysis of
kinesin motility reveals regulation by the cargo-binding tail domain. Nat.
Cell Biol. 1, 293–297
56. Torisawa, T., Ichikawa, M., Furuta, A., Saito, K., Oiwa, K., Kojima, H.,
Toyoshima, Y. Y., and Furuta, K. (2014) Autoinhibition and cooperative
activation mechanisms of cytoplasmic dynein. Nat. Cell Biol. 16, 1118–
1124
57. Wendt, T., Taylor, D., Messier, T., Trybus, K. M., and Taylor, K. A.
(1999) Visualization of head-head interactions in the inhibited state of
smooth muscle myosin. J. Cell Biol. 147, 1385–1389
58. Wendt, T., Taylor, D., Trybus, K. M., and Taylor, K. (2001) Three-
dimensional image reconstruction of dephosphorylated smooth muscle
heavy meromyosin reveals asymmetry in the interaction between myosin
heads and placement of subfragment 2. Proc. Natl. Acad. Sci. U. S. A. 98,
4361–4366
59. Zoghbi, M. E., Woodhead, J. L., Moss, R. L., and Craig, R. (2008) Three-
dimensional structure of vertebrate cardiac muscle myosin filaments.
Proc. Natl. Acad. Sci. U. S. A. 105, 2386–2390
60. Scarff, C. A., Carrington, G., Casas-Mao, D., Chalovich, J. M., Knight, P.
J., Ranson, N. A., and Peckham, M. (2020) Structure of the shutdown
state of myosin-2. Nature 588, 515–520
61. Yang, S., Tiwari, P., Lee, K. H., Sato, O., Ikebe, M., Padrón, R., and Craig,
R. (2020) Cryo-EM structure of the inhibited (10S) form of myosin II.
Nature 588, 521–525
62. Stewart, M. A., Franks-Skiba, K., Chen, S., and Cooke, R. (2010)
Myosin ATP turnover rate is a mechanism involved in thermogenesis
in resting skeletal muscle fibers. Proc. Natl. Acad. Sci. U. S. A. 107,
430–435
JBC REVIEWS: Cardiac myosin in health and disease
12 J. Biol. Chem. (2021) 297(5) 101297
63. Wilson, C., Naber, N., Pate, E., and Cooke, R. (2014) The myosin in-
hibitor blebbistatin stabilizes the super-relaxed state in skeletal muscle.
Biophys. J. 107, 1637–1646
64. Hooijman, P., Stewart, M. A., and Cooke, R. (2011) A new state of
cardiac myosin with very slow ATP turnover: A potential car-
dioprotective mechanism in the heart. Biophys. J. 100, 1969–1976
65. Alamo, L., Wriggers, W., Pinto, A., Bártoli, F., Salazar, L., Zhao, F. Q.,
Craig, R., and Padrón, R. (2008) Three-dimensional reconstruction of
tarantula myosin filaments suggests how phosphorylation may regulate
myosin activity. J. Mol. Biol. 384, 780–797
66. Woodhead, J. L., Zhao, F. Q., Craig, R., Egelman, E. H., Alamo, L., and
Padrón, R. (2005) Atomic model of a myosin filament in the relaxed
state. Nature 436, 1195–1199
67. Al-Khayat, H. A., Kensler, R. W., Squire, J. M., Marston, S. B., and
Morris, E. P. (2013) Atomic model of the human cardiac muscle myosin
filament. Proc. Natl. Acad. Sci. U. S. A. 110, 318–323
68. Anderson, R. L., Trivedi, D. V., Sarkar, S. S., Henze, M., Ma, W., Gong,
H., Rogers, C. S., Gorham, J. M., Wong, F. L., Morck, M. M., Seidman, J.
G., Ruppel, K. M., Irving, T. C., Cooke, R., Green, E. M., et al. (2018)
Deciphering the super relaxed state of human β-cardiac myosin and the
mode of action of mavacamten from myosin molecules to muscle fibers.
Proc. Natl. Acad. Sci. U. S. A. 115, E8143–E8152
69. Spudich, J. A. (2015) The myosin mesa and a possible unifying hy-
pothesis for the molecular basis of human hypertrophic cardiomyopa-
thy. Biochem. Soc. Trans. 43, 64–72
70. Nag, S., Trivedi, D. V., Sarkar, S. S., Adhikari, A. S., Sunitha, M. S.,
Sutton, S., Ruppel, K. M., and Spudich, J. A. (2017) The myosin mesa
and the basis of hypercontractility caused by hypertrophic cardiomy-
opathy mutations. Nat. Struct. Mol. Biol. 24, 525–533
71. Trivedi, D. V., Adhikari, A. S., Sarkar, S. S., Ruppel, K. M., and Spudich,
J. A. (2018) Hypertrophic cardiomyopathy and the myosin mesa:
Viewing an old disease in a new light. Biophys. Rev. 10, 27–48
72. McNamara, J. W., Li, A., Smith, N. J., Lal, S., Graham, R. M., Kooiker, K.
B., van Dijk, S. J., Remedios, C. G. do., Harris, S. P., and Cooke, R. (2016)
Ablation of cardiac myosin binding protein-C disrupts the super-relaxed
state of myosin in murine cardiomyocytes. J. Mol. Cell. Cardiol. 94, 65–71
73. McNamara, J. W., Singh, R. R., and Sadayappan, S. (2019) Cardiac
myosin binding protein-C phosphorylation regulates the super-relaxed
state of myosin. Proc. Natl. Acad. Sci. U. S. A. 116, 11731–11736
74. Davis, J. S., Hassanzadeh, S., Winitsky, S., Wen, H., Aletras, A., and
Epstein, N. D. (2002) A gradient of myosin regulatory light-chain
phosphorylation across the ventricular wall supports cardiac torsion.
Cold Spring Harb. Symp. Quant. Biol. 67, 345–352
75. Yang, Z., Stull, J. T., Levine, R. J. C., and Sweeney, H. L. (1998) Changes
in interfilament spacing mimic the effects of myosin regulatory light
chain phosphorylation in rabbit psoas fibers. J. Struct. Biol. 122, 139–148
76. Sweeney, H. L., and Stull, J. T. (1986) Phosphorylation of myosin in
permeabilized mammalian cardiac and skeletal muscle cells. Am. J.
Physiol. 250, C657–C660
77. Levine, R. J. C., Kensler, R. W., Yang, Z., Stull, J. T., and Sweeney, H. L.
(1996) Myosin light chain phosphorylation affects the structure of rabbit
skeletal muscle thick filaments. Biophys. J. 71, 898–907
78. Linari, M., Brunello, E., Reconditi, M., Fusi, L., Caremani, M., Nar-
ayanan, T., Piazzesi, G., Lombardi, V., and Irving, M. (2015) Force
generation by skeletal muscle is controlled by mechanosensing in
myosin filaments. Nature 528, 276–279
79. Zhang, X., Kampourakis, T., Yan, Z., Sevrieva, I., Irving, M., and Sun, Y.-
B. (2017) Distinct contributions of the thin and thick filaments to
length-dependent activation in heart muscle. Elife 6, e24081
80. Reconditi, M., Caremani, M., Pinzauti, F., Powers, J. D., Narayanan, T.,
Stienen, G. J. M., Linari, M., Lombardi, V., and Piazzesi, G. (2017)
Myosin filament activation in the heart is tuned to the mechanical task.
Proc. Natl. Acad. Sci. U. S. A. 114, 3240–3245
81. Brunello, E., Fusi, L., Ghisleni, A., Park-Holohan, S.-J., Ovejero, J. G.,
Narayanan, T., and Irving, M. (2020) Myosin filament-based regulation
of the dynamics of contraction in heart muscle. Proc. Natl. Acad. Sci. U.
S. A. 117, 8177–8186
82. Ait-Mou, Y., Hsu, K., Farman, G. P., Kumar, M., Greaser, M. L., Irving,
T. C., and de Tombe, P. P. (2016) Titin strain contributes to the
Frank–Starling law of the heart by structural rearrangements of both
thin- and thick-filament proteins. Proc. Natl. Acad. Sci. U. S. A. 113,
2306–2311
83. Caremani, M., Pinzauti, F., Powers, J. D., Governali, S., Narayanan, T.,
Stienen, G. J. M., Reconditi, M., Linari, M., Lombardi, V., and Piazzesi,
G. (2019) Inotropic interventions do not change the resting state of
myosin motors during cardiac diastole. J. Gen. Physiol. 151, 53–65
84. Ma, W., Henze, M., Anderson, R. L., Gong, H., Wong, F. L., del Rio, C.
L., and Irving, T. (2021) The super-relaxed state and length dependent
activation in porcine myocardium. Circ. Res. 129, 617–630
85. de Tombe, P. P., Mateja, R. D., Tachampa, K., Mou, Y. A., Farman, G. P.,
and Irving, T. C. (2010) Myofilament length dependent activation. J.
Mol. Cell. Cardiol. 48, 851–858
86. Fenn, W. O. (1923) A quantitative comparison between the energy
liberated and the work performed by the isolated sartorius muscle of the
frog. J. Physiol. 58, 175–203
87. Hill, A. V. (1938) The heat of shortening and the dynamic constants of
muscle. Proc. R. Soc. B Biol. Sci. 126, 136–195
88. Takagi, Y., Homsher, E. E., Goldman, Y. E., and Shuman, H. (2006)
Force generation in single conventional actomyosin complexes under
high dynamic load. Biophys. J. 90, 1295–1307
89. Capitanio, M., Canepari, M., Maffei, M., Beneventi, D., Monico, C.,
Vanzi, F., Bottinelli, R., and Pavone, F. S. (2012) Ultrafast force-clamp
spectroscopy of single molecules reveals load dependence of myosin
working stroke. Nat. Methods 9, 1013–1019
90. Bárány, M. (1967) ATPase activity of myosin correlated with speed of
muscle shortening. J. Gen. Physiol. 50, 197–218
91. Sung, J., Nag, S., Mortensen, K. I., Vestergaard, C. L., Sutton, S., Ruppel,
K., Flyvbjerg, H., and Spudich, J. A. (2015) Harmonic force spectroscopy
measures load-dependent kinetics of individual human β-cardiac myosin
molecules. Nat. Commun. 6, 7931
92. England, J., and Loughna, S. (2013) Heavy and light roles: Myosin in the
morphogenesis of the heart. Cell. Mol. Life Sci. 70, 1221–1239
93. Hoh, J. F. Y., Yeoh, G. P. S., Thomas, M. A. W., and Higginbottom, L.
(1979) Structural differences in the heavy chains of rat ventricular
myosin isoenzymes. FEBS Lett. 97, 330–334
94. Krenz, M., Sadayappan, S., Osinska, H. E., Henry, J. A., Beck, S., War-
shaw, D. M., and Robbins, J. (2007) Distribution and structure-function
relationship of myosin heavy chain isoforms in the adult mouse heart. J.
Biol. Chem. 282, 24057–24064
95. Deacon, J. C., Bloemink, M. J., Rezavandi, H., Geeves, M. A., and
Leinwand, L. A. (2012) Identification of functional differences between
recombinant human α and β cardiac myosin motors. Cell. Mol. Life Sci.
69, 2261–2277
96. VanBuren, P., Harris, D. E., Alpert, N. R., and Warshaw, D. M. (1995)
Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical
activities in vitro. Circ. Res. 77, 439–444
97. Harris, D. E., Work, S. S., Wright, R. K., Alpert, N. R., and Warshaw, D.
M. (1994) Smooth, cardiac and skeletal muscle myosin force and motion
generation assessed by cross-bridge mechanical interactions in vitro. J.
Muscle Res. Cell Motil. 15, 11–19
98. Guhathakurta, P., Prochniewicz, E., and Thomas, D. D. (2015) Ampli-
tude of the actomyosin power stroke depends strongly on the isoform of
the myosin essential light chain. Proc. Natl. Acad. Sci. U. S. A. 112,
4660–4665
99. Reiser, P. J., Portman, M. A., Ning, X. H., and Moravec, C. S. (2001)
Human cardiac myosin heavy chain isoforms in fetal and failing adult
atria and ventricles. Am. J. Physiol. Heart Circ. Physiol. 280, H1814–
H1820
100. Lowes, B. D., Minobe, W., Abraham, W. T., Rizeq, M. N., Bohlmeyer, T.
J., Quaife, R. A., Roden, R. L., Dutcher, D. L., Robertson, A. O., Voelkel,
N. F., Badesch, D. B., Groves, B. M., Gilbert, E. M., and Bristow, M. R.
(1997) Changes in gene expression in the intact human heart: Down-
regulation of α-myosin heavy chain in hypertrophied, failing ventricular
myocardium. J. Clin. Invest. 100, 2315–2324
JBC REVIEWS: Cardiac myosin in health and disease
J. Biol. Chem. (2021) 297(5) 101297 13
101. Miyata, S., Minobe, W., Bristow, M. R., and Leinwand, L. A. (2000)
Myosin heavy chain isoform expression in the failing and nonfailing
human heart. Circ. Res. 86, 386–390
102. Chopra, A., Kutys, M. L., Zhang, K., Polacheck, W. J., Sheng, C. C., Luu,
R. J., Eyckmans, J., Hinson, J. T., Seidman, J. G., Seidman, C. E., and
Chen, C. S. (2018) Force generation via β-cardiac myosin, titin, and α-
actinin drives cardiac sarcomere assembly from cell-matrix adhesions.
Dev. Cell 44, 87–96
103. Fenix, A. M., Neininger, A. C., Taneja, N., Hyde, K., Visetsouk, M. R.,
Garde, R. J., Liu, B., Nixon, B. R., Manalo, A. E., Becker, J. R., Crawley, S.
W., Bader, D. M., Tyska, M. J., Liu, Q., Gutzman, J. H., et al. (2018)
Muscle-specific stress fibers give rise to sarcomeres in cardiomyocytes.
Elife 7, e42144
104. Clippinger, S. R., Cloonan, P. E., Wang, W., Greenberg, L., Stump, W. T.,
Angsutararux, P., Nerbonne, J. M., and Greenberg, M. J. (2021) Me-
chanical dysfunction of the sarcomere induced by a pathogenic muta-
tion in troponin T drives cellular adaptation. J. Gen. Physiol. 153,
e202012787
105. Clippinger, S. R., Cloonan, P. E., Greenberg, L., Ernst, M., Stump, W. T.,
and Greenberg, M. J. (2019) Disrupted mechanobiology links the mo-
lecular and cellular phenotypes in familial dilated cardiomyopathy. Proc.
Natl. Acad. Sci. U. S. A. 116, 17831–17840
106. Engler, A. J., Carag-Krieger, C., Johnson, C. P., Raab, M., Tang, H. Y.,
Speicher, D. W., Sanger, J. W., Sanger, J. M., and Discher, D. E. (2008)
Embryonic cardiomyocytes beat best on a matrix with heart-like elas-
ticity: Scar-like rigidity inhibits beating. J. Cell Sci. 121, 3794–3802
107. Majkut, S., Idema, T., Swift, J., Krieger, C., Liu, A., and Discher, D. E.
(2013) Heart-specific stiffening in early embryos parallels matrix and
myosin expression to optimize beating. Curr. Biol. 23, 2434–2439
108. Cho, S., Vashisth, M., Abbas, A., Majkut, S., Vogel, K., Xia, Y., Iva-
novska, I. L., Irianto, J., Tewari, M., Zhu, K., Tichy, E. D., Mourkioti, F.,
Tang, H. Y., Greenberg, R. A., Prosser, B. L., et al. (2019) Mechano-
sensing by the lamina protects against nuclear rupture, DNA damage,
and cell-cycle arrest. Dev. Cell 49, 920–935
109. Papadaki, M., Holewinski, R. J., Beck Previs, S., Martin, T. G., Sta-
chowski, M. J., Li, A., Blair, C. A., Moravec, C. S., Van Eyk, J. E.,
Campbell, K. S., Warshaw, D. M., and Kirk, J. A. (2018) Diabetes with
heart failure increases methylglyoxal modifications in the sarcomere,
which inhibit function. JCI Insight 3, e121264
110. Papadaki, M., Kampaengsri, T., Barrick, S. K., Campbell, S. G., von
Lewinski, D., Rainer, P. P., Harris, S. P., Greenberg, M. J., and Kirk, J. A.
(2021) Myofilament glycation in diabetes reduces contractility by
inhibiting tropomyosin movement, is rescued by cMyBPC domains. J.
Mol. Cell. Cardiol. 162, 1–9
111. Rai, R., Wong, C. C. L., Xu, T., Leu, N. A., Dong, D. W., Guo, C.,
McLaughlin, K. J., Yates, J. R., and Kashina, A. (2008) Arginyl-
transferase regulates alpha cardiac actin function, myofibril formation
and contractility during heart development. Development 135, 3881–
3889
112. Schmidt, W., Madan, A., Foster, D. B., and Cammarato, A. (2020) Lysine
acetylation of F-actin decreases tropomyosin-based inhibition of acto-
myosin activity. J. Biol. Chem. 295, 15527–15539
113. Burke, M. A., Cook, S. A., Seidman, J. G., and Seidman, C. E. (2016)
Clinical and mechanistic insights into the genetics of cardiomyopathy. J.
Am. Coll. Cardiol. 68, 2871–2886
114. Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P.,
McDonough, B., Smoot, L., Mullen, M. P., Woolf, P. K., Wigle, E. D.,
Seidman, J. G., Jarcho, J., Shapiro, L. R., and Seidman, C. E. (2000)
Mutations in sarcomere protein genes as a cause of dilated cardiomy-
opathy. N. Engl. J. Med. 343, 1688–1696
115. Marian, A. J., and Braunwald, E. (2017) Hypertrophic cardiomyopathy:
Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy.
Circ. Res. 121, 749–770
116. Klaassen, S., Probst, S., Oechslin, E., Gerull, B., Krings, G., Schuler, P.,
Greutmann, M., Hürlimann, D., Yegitbasi, M., Pons, L., Gramlich, M.,
Drenckhahn, J. D., Heuser, A., Berger, F., Jenni, R., et al. (2008) Muta-
tions in sarcomere protein genes in left ventricular noncompaction.
Circulation 117, 2893–2901
117. Tajsharghi, H., and Oldfors, A. (2013) Myosinopathies: Pathology and
mechanisms. Acta Neuropathol. 125, 3–18
118. Ching, Y. H., Ghosh, T. K., Cross, S. J., Packham, E. A., Honeyman, L.,
Loughna, S., Robinson, T. E., Dearlove, A. M., Ribas, G., Bonser, A. J.,
Thomas, N. R., Scotter, A. J., Caves, L. S. D., Tyrrell, G. P., Newbury-
Ecob, R. A., et al. (2005) Mutation in myosin heavy chain 6 causes atrial
septal defect. Nat. Genet. 37, 423–428
119. Holm, H., Gudbjartsson, D. F., Sulem, P., Masson, G., Helgadottir, H. T.,
Zanon, C., Magnusson, O. T., Helgason, A., Saemundsdottir, J., Gylfa-
son, A., Stefansdottir, H., Gretarsdottir, S., Matthiasson, S. E., Thor-
geirsson, G., Jonasdottir, A., et al. (2011) A rare variant in MYH6 is
associated with high risk of sick sinus syndrome. Nat. Genet. 43, 316–
323
120. Greenberg, M. J., and Tardiff, J. C. (2021) Complexity in genetic car-
diomyopathies and new approaches for mechanism-based precision
medicine. J. Gen. Physiol. 153, e202012662
121. Geisterfer-Lowrance, A. A., Kass, S., Tanigawa, G., Vosberg, H.-P.,
McKenna, W., Seidman, C. E., and Seidman, J. G. (1990) A molecular
basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin
heavy chain gene missense mutation. Cell 62, 999–1006
122. Tanigawa, G., Jarcho, J. A., Kass, S., Solomon, S. D., Vosberg, H. P.,
Seidman, J. G., and Seidman, C. E. (1990) A molecular basis for familial
hypertrophic cardiomyopathy: An α β cardiac myosin heavy chain
hybrid gene. Cell 62, 991–998
123. Moore, J. R., Leinwand, L., and Warshaw, D. M. (2012) Understanding
cardiomyopathy phenotypes based on the functional impact of muta-
tions in the myosin motor. Circ. Res. 111, 375–385
124. Mestroni, L., Maisch, B., McKenna, W. J., Schwartz, K., Charron, P.,
Rocco, C., Tesson, F., Richter, A., Wilke, A., and Komajda, M. (1999)
Guidelines for the study of familial dilated cardiomyopathies. Eur. Heart
J. 20, 93–102
125. McNally, E. M., and Mestroni, L. (2017) Dilated cardiomyopathy: Ge-
netic determinants and mechanisms. Circ. Res. 121, 731–748
126. Akhtar, M. M., and Elliott, P. (2018) The genetics of hypertrophic
cardiomyopathy. Glob. Cardiol. Sci. Pract. https://doi.org/10.1093/
eurheartj/ehu284
127. Davis, J., Davis, L. C., Correll, R. N., Makarewich, C. A., Schwanekamp,
J. A., Moussavi-Harami, F., Wang, D., York, A. J., Wu, H., Houser, S. R.,
Seidman, C. E., Seidman, J. G., Regnier, M., Metzger, J. M., Wu, J. C.,
et al. (2016) A tension-based model distinguishes hypertrophic versus
dilated cardiomyopathy. Cell 165, 1147–1159
128. Powers, J. D., Kooiker, K. B., Mason, A. B., Teitgen, A. E., Flint, G. V.,
Tardiff, J. C., Schwartz, S. D., McCulloch, A. D., Regnier, M., Davis, J.,
and Moussavi-Harami, F. (2020) Modulating the tension-time integral of
the cardiac twitch prevents dilated cardiomyopathy in murine hearts.
JCI Insight 5, e142446
129. Campbell, S. G., Lionetti, F. V., Campbell, K. S., and McCulloch, A. D.
(2010) Coupling of adjacent tropomyosins enhances cross-bridge-
mediated cooperative activation in a markov model of the cardiac thin
filament. Biophys. J. 98, 2254–2264
130. Malmqvist, U. P., Aronshtam, A., and Lowey, S. (2004) Cardiac myosin
isoforms from different species have unique enzymatic and mechanical
properties. Biochemistry 43, 15058–15065
131. Greenberg, M. J., Kazmierczak, K., Szczesna-Cordary, D., and Moore, J.
R. (2010) Cardiomyopathy-linked myosin regulatory light chain muta-
tions disrupt myosin strain-dependent biochemistry. Proc. Natl. Acad.
Sci. U. S. A. 107, 17403–17408
132. Lowey, S., Lesko, L. M., Rovner, A. S., Hodges, A. R., White, S. L., Low,
R. B., Rincon, M., Gulick, J., and Robbins, J. (2008) Functional effects of
the hypertrophic cardiomyopathy R403Q mutation are different in an
alpha- or beta-myosin heavy chain backbone. J. Biol. Chem. 283, 20579–
20589
133. Lowey, S., Bretton, V., Gulick, J., Robbins, J., and Trybus, K. M. (2013)
Transgenic mouse α- and β-cardiac myosins containing the R403Q
mutation show isoform-dependent transient kinetic differences. J. Biol.
Chem. 288, 14780–14787
134. Tyska, M. J., Hayes, E., Giewat, M., Seidman, C. E., Seidman, J. G., and
Warshaw, D. M. (2000) Single-molecule mechanics of R403Q cardiac
JBC REVIEWS: Cardiac myosin in health and disease
14 J. Biol. Chem. (2021) 297(5) 101297
myosin isolated from the mouse model of familial hypertrophic car-
diomyopathy. Circ. Res. 86, 737–744
135. Rasicci, D., Kirkland, Orville, J., Moonschi, F. H., Wood, N. B., Szczesna-
Cordary, D., Previs, M. J., Wenk, J. F., Campbell, K. S., and Yengo, C. M.
(2021) Impact of regulatory light chain mutation K104E on the ATPase
and motor properties of cardiac myosin. J. Gen. Physiol. 153,
e202012811
136. Greenberg, M. J., Watt, J. D., Jones, M., Kazmierczak, K., Szczesna-
Cordary, D., and Moore, J. R. (2009) Regulatory light chain mutations
associated with cardiomyopathy affect myosin mechanics and kinetics.
J. Mol. Cell. Cardiol. 46, 108–115
137. Cuda, G., Fananapazir, L., Epstein, N. D., and Sellers, J. R. (1997) The
in vitro motility activity of β-cardiac myosin depends on the nature of
the β-myosin heavy chain gene mutation in hypertrophic cardiomyop-
athy. J. Muscle Res. Cell Motil. 18, 275–283
138. Palmiter, K. A., Tyska, M. J., Haeberle, J. R., Alpert, N. R., Fananapazir,
L., and Warshaw, D. M. (2000) R403Q and L908V mutant β-cardiac
myosin from patients with familial hypertrophic cardiomyopathy exhibit
enhanced mechanical performance at the single molecule level. J. Muscle
Res. Cell Motil. 21, 609–620
139. Srikakulam, R., and Winkelmann, D. A. (1999) Myosin II folding is
mediated by a molecular chaperonin. J. Biol. Chem. 274, 27265–27273
140. Chow, D., Srikakulam, R., Chen, Y., and Winkelmann, D. A. (2002)
Folding of the striated muscle myosin motor domain. J. Biol. Chem. 277,
36799–36807
141. Srikakulam, R., and Winkelmann, D. A. (2004) Chaperone-mediated
folding and assembly of myosin in striated muscle. J. Cell Sci. 117, 641–
652
142. Resnicow, D. I., Deacon, J. C., Warrick, H. M., Spudich, J. A., and
Leinwand, L. A. (2010) Functional diversity among a family of human
skeletal muscle myosin motors. Proc. Natl. Acad. Sci. U. S. A. 107, 1053–
1058
143. Spudich, J. A., Aksel, T., Bartholomew, S. R., Nag, S., Kawana, M., Yu, E.
C., Sarkar, S. S., Sung, J., Sommese, R. F., Sutton, S., Cho, C., Adhikari,
A. S., Taylor, R., Liu, C., Trivedi, D. V., et al. (2016) Effects of hyper-
trophic and dilated cardiomyopathy mutations on power output by
human β-cardiac myosin. J. Exp. Biol. 219, 161–167
144. Gunther, L. K., Rohde, J. A., Tang, W., Walton, S. D., Unrath, W. C.,
Trivedi, D. V., Muretta, J. M., Thomas, D. D., and Yengo, C. M. (2019)
Converter domain mutations in myosin alter structural kinetics and
motor function. J. Biol. Chem. 294, 1554–1567
145. Nag, S., Sommese, R. F., Ujfalusi, Z., Combs, A., Langer, S., Sutton, S.,
Leinwand, L. A., Geeves, M. A., Ruppel, K. M., and Spudich, J. A. (2015)
Contractility parameters of human β-cardiac myosin with the hyper-
trophic cardiomyopathy mutation R403Q show loss of motor function.
Sci. Adv. 1, e1500511
146. Sarkar, S. S., Trivedi, D. V., Morck, M. M., Adhikari, A. S., Pasha, S. N.,
Ruppel, K. M., and Spudich, J. A. (2020) The hypertrophic cardiomy-
opathy mutations R403Q and R663H increase the number of myosin
heads available to interact with actin. Sci. Adv. 6, eaax0069
147. Adhikari, A. S., Trivedi, D. V., Sarkar, S. S., Song, D., Kooiker, K. B.,
Bernstein, D., Spudich, J. A., and Ruppel, K. M. (2019) β-Cardiac myosin
hypertrophic cardiomyopathy mutations release sequestered heads and
increase enzymatic activity. Nat. Commun. 10, 2685
148. Spudich, J. A. (2019) Three perspectives on the molecular basis of
hypercontractility caused by hypertrophic cardiomyopathy mutations.
Pflugers Arch. 471, 701–717
149. Toepfer, C. N., Garfinkel, A. C., Venturini, G., Wakimoto, H., Repetti,
G., Alamo, L., Sharma, A., Agarwal, R., Ewoldt, J. F., Cloonan, P.,
Letendre, J., Lun, M., Olivotto, I., Colan, S., Ashley, E., et al. (2020)
Myosin sequestration regulates sarcomere function, cardiomyocyte en-
ergetics, and metabolism, informing the pathogenesis of hypertrophic
cardiomyopathy. Circulation 141, 828–842
150. Ujfalusi, Z., Vera, C. D., Mijailovich, S. M., Svicevic, M., Yu, E. C.,
Kawana, M., Ruppel, K. M., Spudich, J. A., Geeves, M. A., and Lein-
wand, L. A. (2018) Dilated cardiomyopathy myosin mutants have
reduced force-generating capacity. J. Biol. Chem. 293, 9017–9029
151. Alamo, L., Ware, J. S., Pinto, A., Gillilan, R. E., Seidman, J. G., Seidman,
C. E., and Padrón, R. (2017) Effects of myosin variants on interacting-
heads motif explain distinct hypertrophic and dilated cardiomyopathy
phenotypes. Elife 6, e24634
152. Xia, Y., Chen, S., Yang, Y., Wu, Y., Huang, S., Wang, Y., Ding, H., He,
W., Li, P., and Zhuang, J. (2019) Novel mutation in MYH6 in 2 unrelated
Chinese Han families with familial atrial septal defect. Circ. Genom.
Precis. Med. 12, 529–531
153. Posch, M. G., Waldmuller, S., Müller, M., Scheffold, T., Fournier, D.,
Andrade-Navarro, M. A., de Geeter, B., Guillaumont, S., Dauphin, C.,
Yousseff, D., Schmitt, K. R., Perrot, A., Berger, F., Hetzer, R., Bouvagnet,
P., et al. (2011) Cardiac alpha-myosin (MYH6) is the predominant
sarcomeric disease gene for familial atrial septal defects. PLoS One 6,
e28872
154. Ho, C. Y., Day, S. M., Ashley, E. A., Michels, M., Pereira, A. C., Jacoby,
D., Cirino, A. L., Fox, J. C., Lakdawala, N. K., Ware, J. S., Caleshu, C. A.,
Helms, A. S., Colan, S. D., Girolami, F., Cecchi, F., et al. (2018) Genotype
and lifetime burden of disease in hypertrophic cardiomyopathy insights
from the sarcomeric human cardiomyopathy registry (SHaRe). Circu-
lation 138, 1387–1398
155. Spirito, P., Maron, B. J., Chiarella, F., Bellotti, P., Tramarin, R., Pozzoli,
M., and Vecchio, C. (1985) Diastolic abnormalities in patients with
hypertrophic cardiomyopathy: Relation to magnitude of left ventricular
hypertrophy. Circulation 72, 310–316
156. Lorenzini, M., Norrish, G., Field, E., Ochoa, J. P., Cicerchia, M., Akhtar,
M. M., Syrris, P., Lopes, L. R., Kaski, J. P., and Elliott, P. M. (2020)
Penetrance of hypertrophic cardiomyopathy in sarcomere protein mu-
tation carriers. J. Am. Coll. Cardiol. 76, 550–559
157. Robinson, P., Liu, X., Sparrow, A., Patel, S., Zhang, Y. H., Casadei, B.,
Watkins, H., and Redwood, C. (2018) Hypertrophic cardiomyopathy
mutations increase myofilament Ca2+ buffering, alter intracellular Ca2+
handling, and stimulate Ca2+-dependent signaling. J. Biol. Chem. 293,
10487–10499
158. Ho, C. Y., López, B., Coelho-Filho, O. R., Lakdawala, N. K., Cirino, A. L.,
Jarolim, P., Kwong, R., González, A., Colan, S. D., Seidman, J. G., Díez, J.,
and Seidman, C. E. (2010) Myocardial fibrosis as an early manifestation
of hypertrophic cardiomyopathy. N. Engl. J. Med. 363, 552–563
159. Bulkley, B. H., D’Amico, B., and Taylor, A. L. (1983) Extensive
myocardial fiber disarray in aortic and pulmonary atresia. Relevance to
hypertrophic cardiomyopathy. Circulation 67, 191–198
160. Maron, B. J., Towbin, J. A., Thiene, G., Antzelevitch, C., Corrado, D.,
Arnett, D., Moss, A. J., Seidman, C. E., Young, J. B., American Heart
Association, Council on Clinical Cardiology, Heart Failure and Trans-
plantation Committee, Quality of Care and Outcomes Research and
Functional Genomics and Translational Biology Interdisciplinary
Working Groups, and Council on Epidemiology and Prevention. (2006)
Contemporary definitions and classification of the cardiomyopathies: An
American Heart Association scientific statement from the Council on
Clinical Cardiology, Heart Failure and Transplantation Committee;
Quality of Care and Outcomes Research and Functional Genomics and
Translational Biology Interdisciplinary Working Groups; and Council on
Epidemiology and Prevention. Circulation 113, 1807–1816
161. Harvey, P. A., and Leinwand, L. A. (2011) Cellular mechanisms of car-
diomyopathy. J. Cell Biol. 194, 355–365
162. Chen, C. Y., Caporizzo, M. A., Bedi, K., Vite, A., Bogush, A. I., Robison,
P., Heffler, J. G., Salomon, A. K., Kelly, N. A., Babu, A., Morley, M. P.,
Margulies, K. B., and Prosser, B. L. (2018) Suppression of detyrosinated
microtubules improves cardiomyocyte function in human heart failure.
Nat. Med. 24, 1225–1233
163. Schuldt, M., Pei, J., Harakalova, M., Dorsch, L. M., Schlossarek, S.,
Mokry, M., Knol, J. C., Pham, T. V., Schelfhorst, T., Piersma, S. R., Dos
Remedios, C., Dalinghaus, M., Michels, M., Asselbergs, F. W., and
Moutin, M. J. (2021) Proteomic and functional studies reveal detyrosi-
nated tubulin as treatment target in sarcomere mutation-induced hy-
pertrophic cardiomyopathy. Circ. Heart Fail. 14, e007022
164. Davis, J., and Molkentin, J. D. (2014) Myofibroblasts: Trust your heart
and let fate decide. J. Mol. Cell. Cardiol. 70, 9–18
JBC REVIEWS: Cardiac myosin in health and disease
J. Biol. Chem. (2021) 297(5) 101297 15
165. Nakamura, M., and Sadoshima, J. (2018) Mechanisms of physiological
and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387–407
166. Lavine, K. J., and Greenberg, M. J. (2021) Beyond genomics—techno-
logical advances improving the molecular characterization and precision
treatment of heart failure. Heart Fail. Rev. 26, 405–415
167. Kantor, P. F., Abraham, J. R., Dipchand, A. I., Benson, L. N., and Red-
ington, A. N. (2010) The impact of changing medical therapy on
transplantation-free survival in pediatric dilated cardiomyopathy. J. Am.
Coll. Cardiol. 55, 1377–1384
168. Morgan, B. P., Muci, A., Lu, P. P., Qian, X., Tochimoto, T., Smith, W.
W., Garard, M., Kraynack, E., Collibee, S., Suehiro, I., Tomasi, A., Val-
dez, S. C., Wang, W., Jiang, H., Hartman, J., et al. (2010) Discovery of
omecamtiv mecarbil the first, selective, small molecule activator of
cardiac myosin. ACS Med. Chem. Lett. 1, 472–477
169. Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M.,
Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-
Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R.,
Crespo-Leiro, M. G., et al. (2021) Cardiac myosin activation with
omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105–
116
170. Malik, F. I., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T.,
Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K.,
Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., Sakowicz, R., et al.
(2011) Cardiac myosin activation: A potential therapeutic approach for
systolic heart failure. Science 331, 1439–1443
171. Liu, Y., White, H. D., Belknap, B., Winkelmann, D. A., and Forgacs, E.
(2015) Omecamtiv mecarbil modulates the kinetic and motile properties
of porcine β-cardiac myosin. Biochemistry 54, 1963–1975
172. Rohde, J. A., Thomas, D. D., and Muretta, J. M. (2017) Heart failure drug
changes the mechanoenzymology of the cardiac myosin powerstroke.
Proc. Natl. Acad. Sci. U. S. A. 114, E1796–E1804
173. Liu, C., Kawana, M., Song, D., Ruppel, K. M., and Spudich, J. A. (2018)
Controlling load-dependent kinetics of β-cardiac myosin at the single-
molecule level. Nat. Struct. Mol. Biol. 25, 505–514
174. Nagy, L., Kovács, Bõdi, B., Pásztor, E. T., Fülöp, G., Tõth, A., Édes, I., and
Papp, Z. (2015) The novel cardiac myosin activator omecamtiv mecarbil
increases the calcium sensitivity of force production in isolated car-
diomyocytes and skeletal muscle fibres of the rat. Br. J. Pharmacol. 172,
4506–4518
175. Kampourakis, T., Zhang, X., Sun, Y. B., and Irving, M. (2018) Ome-
camtiv mercabil and blebbistatin modulate cardiac contractility by
perturbing the regulatory state of the myosin filament. J. Physiol. 596,
31–46
176. Fernandes, S., Oikonomopoulos, A., Jimenez-MacInnes, S. K., Aschar-
Sobbi, R., Henze, M., Sumandea, M., Gan, Q.-F., Anderson, R. L., and del
Rio, C. L. (2019) Abstract 15707: MYK-491, a novel small-molecule
cardiac myosin activator increases cardiac systolic function and pre-
serves mechanical efficiency: Pre-clinical in vivo and in vitro evidence.
Circulation 140, A15707
177. Voors, A. A., Tamby, J. F., Cleland, J. G., Koren, M., Forgosh, L. B.,
Gupta, D., Lund, L. H., Camacho, A., Karra, R., Swart, H. P., Pellicori, P.,
Wagner, F., Hershberger, R. E., Prasad, N., Anderson, R. L., et al. (2020)
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure
with reduced ejection fraction: Experimental data and clinical results
from a phase 2a trial. Eur. J. Heart Fail. 22, 1649–1658
178. Regnier, M., Lee, D. M., and Homsher, E. (1998) ATP analogs and
muscle contraction: Mechanics and kinetics of nucleoside triphosphate
binding and hydrolysis. Biophys. J. 74, 3044–3058
179. Shimizu, T., Furusawa, K., Ohashi, S., Toyoshima, Y. Y., Okuno, M.,
Malik, F. I., and Vale, R. D. (1991) Nucleotide specificity of the enzy-
matic and motile activities of dynein, kinesin, and heavy meromyosin.
J. Cell Biol. 112, 1189–1197
180. Powers, J. D., Yuan, C. C., McCabe, K. J., Murray, J. D., Childers, M. C.,
Flint, G. V., Moussavi-Harami, F., Mohran, S., Castillo, R., Zuzek, C.,
Ma, W., Daggett, V., McCulloch, A. D., Irving, T. C., and Regnier, M.
(2019) Cardiac myosin activation with 2-deoxy-ATP via increased
electrostatic interactions with actin. Proc. Natl. Acad. Sci. U. S. A. 166,
11502–11507
181. Korte, F. S., Dai, J., Buckley, K., Feest, E. R., Adamek, N., Geeves, M. A.,
Murry, C. E., and Regnier, M. (2011) Upregulation of cardiomyocyte
ribonucleotide reductase increases intracellular 2 deoxy-ATP, contrac-
tility, and relaxation. J. Mol. Cell. Cardiol. 51, 894–901
182. Lundy, S. D., Murphy, S. A., Dupras, S. K., Dai, J., Murry, C. E.,
Laflamme, M. A., and Regnier, M. (2014) Cell-based delivery of dATP
via gap junctions enhances cardiac contractility. J. Mol. Cell. Cardiol. 72,
350–359
183. Kolwicz, S. C., Odom, G. L., Nowakowski, S. G., Moussavi-Harami, F.,
Chen, X., Reinecke, H., Hauschka, S. D., Murry, C. E., Mahairas, G. G.,
and Regnier, M. (2016) AAV6-mediated cardiac-specific overexpression
of ribonucleotide reductase enhances myocardial contractility. Mol.
Ther. 24, 240–250
184. Nowakowski, S. G., Kolwicz, S. C., Korte, F. S., Luo, Z., Robinson-
Hamm, J. N., Page, J. L., Brozovich, F., Weiss, R. S., Tian, R., Murry, C.
E., and Regnier, M. (2013) Transgenic overexpression of ribonucleotide
reductase improves cardiac performance. Proc. Natl. Acad. Sci. U. S. A.
110, 6187–6192
185. Kadota, S., Carey, J., Reinecke, H., Leggett, J., Teichman, S., Laflamme,
M. A., Murry, C. E., Regnier, M., and Mahairas, G. G. (2015) Ribonu-
cleotide reductase-mediated increase in dATP improves cardiac per-
formance via myosin activation in a large animal model of heart failure.
Eur. J. Heart Fail. 17, 772–781
186. Regnier, M., Rivera, A. J., Chen, Y., and Chase, P. B. (2000) 2-Deoxy-
ATP enhances contractility of rat cardiac muscle. Circ. Res. 86, 1211–
1217
187. Cheng, Y., Hogarth, K. A., O’Sullivan, M. L., Regnier, M., and Pyle, W.
G. (2016) 2-Deoxyadenosine triphosphate restores the contractile
function of cardiac myofibril from adult dogs with naturally occurring
dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 310, H80–
H91
188. Moussavi-Harami, F., Razumova, M. V., Racca, A. W., Cheng, Y.,
Stempien-Otero, A., and Regnier, M. (2015) 2-Deoxy adenosine
triphosphate improves contraction in human end-stage heart failure. J.
Mol. Cell. Cardiol. 79, 256–263
189. Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link,
M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H.,
Seidman, C. E., Towbin, J. A., Udelson, J. E., Yancy, C. W., Anderson, J.
L., et al. (2011) 2011 ACCF/AHA guideline for the diagnosis and
treatment of hypertrophic cardiomyopathy: A report of the American
College of Cardiology Foundation/American Heart Association task
force on practice guidelines developed in collaboration with the
American Ass. J. Am. Coll. Cardiol. 58, 212–260
190. Green, E. M., Wakimoto, H., Anderson, R. L., Evanchik, M. J., Gorham,
J. M., Harrison, B. C., Henze, M., Kawas, R., Oslob, J. D., Rodriguez, H.
M., Song, Y., Wan, W., Leinwand, L. A., Spudich, J. A., McDowell, R. S.,
et al. (2016) Heart disease: A small-molecule inhibitor of sarcomere
contractility suppresses hypertrophic cardiomyopathy in mice. Science
351, 617–621
191. Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A.,
Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A.,
Kubanek, M., Wojakowski, W., Jensen, M. K., Gimeno-Blanes, J.,
Afshar, K., et al. (2020) Mavacamten for treatment of symptomatic
obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396,
759–769
JBC REVIEWS: Cardiac myosin in health and disease
16 J. Biol. Chem. (2021) 297(5) 101297
